IMR Press / FBS / Volume 15 / Issue 4 / DOI: 10.31083/j.fbs1504017
Open Access Short Communication
Effect of 5-aminolevulinic Acid on Mitochondrial Activity
Show Less
1 Laboratory of Cellular and Molecular Pathology of Cardiovascular System, Avtsyn Research Institute of Human Morphology of FSBSI “Petrovsky National Research Centre of Surgery”, 119991 Moscow, Russia
2 Medical Institute, Рeoples’ Friendship University of Russia named after Patrice Lumumba (RUDN University), 117198 Moscow, Russia
3 Department of Biophysics, Faculty of Biology, Lomonosov Moscow State University, 119991 Moscow, Russia
*Correspondence: yu.v.markina@gmail.com (Yuliya V. Markina)
Front. Biosci. (Schol Ed) 2023, 15(4), 17; https://doi.org/10.31083/j.fbs1504017
Submitted: 2 October 2023 | Revised: 28 November 2023 | Accepted: 5 December 2023 | Published: 27 December 2023
Copyright: © 2023 The Author(s). Published by IMR Press.

This is an open access article under the CC BY 4.0 license.

Abstract

Background: Mitochondrial dysfunction is considered an important mechanism in the pathogenesis of various diseases. Therefore, mitochondria are currently being considered as subjects for targeted therapies, particularly, phototherapy using 5-aminolevulinic acid. This study aimed to investigate the activity of mitochondria in cells with different mutation loads. Materials and Methods: The study was conducted using 11 cybrid lines obtained from the THP-1 cell line (a human monocytic leukemia cell line) and platelets of patients with different mitochondrial mutations. Results: Our results illustrate that 5-aminolevulinic acid was metabolized equally in all cell lines, however, there was a significant decrease in mitochondrial potential, which differed among lines. Conclusions: The results of this study can be used to develop a personalized therapeutic approach based on different mitochondrial activities.

Keywords
5-aminolevulinic acid
protoporphyrin IX
mitochondria
targeted photodynamic therapy
Funding
# 22-25-00190/Russian Science Foundation
Figures
Fig. 1.
Share
Back to top